engleski

Subtumoral and intratumoral applications of human natural leucocytic interferon and recombinant human interferon α 2c in patients with cancers of the head and neck.

Totally 23 patients have been treated with HNLI (ca. baseocellulare 14 cases and ca. planocellulare 9 cases) and 18 patients with r.IFN alpha 2c (ca. baseocellulare 10 cases and ca. planocellulare 8 cases). Duration of treatment was 3-6 weeks and 400.00-1.200.00 units of HNLI were applied daily except for Saturday and Sunday. Duration of treatmen in case of r.IFN alpha 2c was 4 weeks, single dose was 2.000.000-5.000.000 units applied daily except for Saturday and Sunday. Bioptic material was taken before and after the treatment. After the treatment with HNLI in 17 out of 23 patients cancerous cells were not found in the material taken after interferon treatment for the second biopsy. After the treatment with r.IFN alpha 2c in 9 patients out of 18 cancerous cells were not found in the second biopsy. Immunohistological process of cure of tumours with HNLI and r.IFN alpha 2c has been the same. Both types of interferon r.IFN alpha 2c and HNLI are both clinically and pathohistologically very effective.

basal cell carcinoma; sqamous cell carcinoma; r.IFN alpha 2c

nije evidentirano